To Frontida BioPharm
Sun Pharmaceutical Industries announced that as a part of its manufacturing consolidation in the US, one of its wholly owned subsidiaries has entered into an agreement with Frontida BioPharm, Inc. for divestment of its two oral solid dosage manufacturing facilities located at Philadelphia, PA and Aurora, IL both in the US, along with 15 related pharmaceutical products.In connection with the transaction, Frontida has agreed to continue manufacturing certain products for Sun Pharma at these facilities on a contract basis for a predetermined period. It has also agreed to offer employment to all production, quality and administrative personnel at the sites. During the divestment process, Sun Pharma was cognizant about ensuring the continued supply of quality products to patients and protecting the interests of its employees working in these units.
Powered by Capital Market - Live News
